COST-EFFECTIVENESS ANALYSIS OF IXEKIZUMAB VERSUS SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND CONCOMITANT MODERATE-TO-SEVERE PSORIASIS IN SPAIN

被引：1
|
作者：
Schweikert, B. [1 ]
Storck, C. T. [1 ]
Nunez, M. [2 ]
Dilla, T. [3 ]
Hartz, S. [4 ]
Sapin, C. [5 ]
机构：
[1] ICON, Munich, Germany
[2] Eli Lilly & Co, Alcobendas, Spain
[3] Lilly Spain, Madrid, Spain
[4] Eli Lilly & Co, Windlesham, Surrey, England
[5] Eli Lilly & Co, Neuilly Sur Seine, France
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.1902
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMU66
引用
收藏
页码：S319 / S319
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF SECUKINUMAB COMPARED WITH USTEKINUMAB AND ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Tzanetakos, C.
    Kourlaba, G.
    Chatzikou, M.
    Antoniou, C.
    Ioannidis, D.
    Lefaki, I
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, A.
    Sotiriadis, D.
    Maniadakis, N.
    VALUE IN HEALTH, 2016, 19 (07) : A569 - A569
  • [22] Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece
    Tzanetakos, C.
    Kourlaba, G.
    Hatzikou, M.
    Antoniou, C.
    Ioannides, D.
    Lefaki, I.
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, V.
    Sotiriadis, D.
    Maniadakis, N.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 61 - 62
  • [23] COST-EFFECTIVENESS OF APREMILAST IN MODERATE-TO-SEVERE PSORIASIS IN CANADA
    Cawston, H.
    Damera, V
    Ektare, V
    Shear, N. H.
    Tencer, T.
    Liu, F. F.
    VALUE IN HEALTH, 2016, 19 (07) : A587 - A587
  • [24] Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
    Zhang, Jinsui
    Xia, Zemin
    Guo, Wanjie
    Ren, Xiaoxiao
    Liu, Fang
    Ratnaparkhi, Gargi
    Pagada, Amit
    Subramanian, Subhashini
    Hu, Min
    Chen, Wen
    DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2681 - 2696
  • [25] Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
    Jinsui Zhang
    Zemin Xia
    Wanjie Guo
    Xiaoxiao Ren
    Fang Liu
    Gargi Ratnaparkhi
    Amit Pagada
    Subhashini Subramanian
    Min Hu
    Wen Chen
    Dermatology and Therapy, 2023, 13 : 2681 - 2696
  • [26] Comment on "Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis"
    Lebwohl, Mark G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (06) : E377 - E377
  • [27] Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis
    Tsao, Nicole W.
    Shojania, Kam
    Marra, Carlo A.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (01) : 9 - 18
  • [28] Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China
    Tian, Lei
    Xiong, Xiaomo
    Guo, Qiang
    Chen, Yixi
    Wang, Luying
    Dong, Peng
    Ma, Aixia
    PHARMACOECONOMICS, 2020, 38 (12) : 1345 - 1358
  • [29] Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China
    Lei Tian
    Xiaomo Xiong
    Qiang Guo
    Yixi Chen
    Luying Wang
    Peng Dong
    Aixia Ma
    PharmacoEconomics, 2020, 38 : 1345 - 1358
  • [30] COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN PSORIATIC ARTHRITIS: A CANADIAN PERSPECTIVE
    Goeree, R.
    Gladman, D.
    Chiva-Razavi, S.
    Gunda, P.
    Graham, C. N.
    Miles, L.
    Nikoglou, E.
    Jugl, S. M.
    VALUE IN HEALTH, 2017, 20 (05) : A145 - A145
12345